DBV Technologies S.A. (NASDAQ:DBVT) Q2 2024 Earnings Conference Call July 30, 2024 5:30 PM ET Company Participants Katie Matthews – Investor Relations Daniel Tassé – Chief Executive Officer Pharis Mohideen – Chief Medical Officer Virginie Boucinha – Chief Financial Officer Conference Call Participants Jon Wolleben – Citizens JMP Operator Welcome to the DBV Second Quarter Financial Results and Business Update Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today ...

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report The 2024 Half-Year Report can be consulted or downloaded from the Company's website (www.dbvtechnologies.com) in the section Investors/Financial Information, and on the AMF website (www.amffrance.org), in French only. by mail : DBV Technologies – 107 avenue de la République 92320 Châtillon, France ; by email: investors@dbv-technologies.com. DBV Technologies is a clinical-stage biopharmaceutical com ...

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report The 2024 Half-Year Report can be consulted or downloaded from the Company's website (www.dbvtechnologies.com) in the section Investors/Financial Information, and on the AMF website (www.amffrance.org), in French only. by mail : DBV Technologies – 107 avenue de la République 92320 Châtillon, France ; by email: investors@dbv-technologies.com. DBV Technologies is a clinical-stage biopharmaceutical com ...

Exhibit 99.1 • VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expected to be complete by end of Q3 2024 • DBV submitted a labeling proposal, informed by the EPITOPE efficacy data, to the Food and Drug Administration (FDA) to address the FDA's protocol queries regarding patch wear-time in COMFORT Toddlers • DBV closes Q2 2024 with a cash balance of $66.2 million; due to cost-saving measures, the Company's cash runway is extended into Q1 2025 COMFORT Toddlers "On April 29th ...

The Company has incurred operating losses and negative cash flows from operations since inception. As of July 30th, DBV's available cash and cash equivalents are not projected to be sufficient to support the Company's operating plan for at least the next 12 months. As such, there is substantial doubt regarding its ability to continue as a going concern. The Company intends to seek additional capital as it continues research and development efforts and prepares for the launch of Viaskin Peanut, if approved. ...

DBV Technologies S.A. (Registrant) | --- | --- | --- | |-------|----------------------------------------------------------------------------------------------------------|-------| | By: | /s/ Daniel Tassé | | | | Daniel Tassé | | | | Chief Executive Of icer (Principal Executive Of icer) | | | By: | /s/ Virginie Boucinha | | | | Virginie Boucinha Chief Financial Of icer (Principal Financial and Accounting Of icer) | | Date: July 30, 2024 24 See "Note 2: Significant Events and Transactions – Legal Proceedings ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update. DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Tick ...

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 Interested participants may access this call via the below teleconferencing numbers and asking to join the DBV Technologies call: A live webcast of the call will be available on the Investors & Media section of the Company's website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV's website after the event. DBV Technologies is a clinical-stage ...

Media Contact Angela Marcucci DBV Technologies angela.marcucci@dbv-technologies.com AMF Regulated Information Montrouge, France, July 8, 2024 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appea ...

AMF Regulated Information Montrouge, France, July 8, 2024 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2024: 303,744 DBV Technologies shares, € ...